Friday, December 12, 2014

3-D mammography improves cancer detection in dense breasts

3-D mammography improves cancer detection in dense breasts

A major new study being presented at the annual meeting of the Radiological Society of North America (RSNA) has found that digital breast tomosynthesis, also known as 3-D mammography, has the potential to significantly increase the cancer detection rate in mammography screening of women with dense breasts.

Breasts are considered dense if they have a lot of fibrous or glandular tissue but not much fatty tissue. Research has shown that dense breasts are more likely to develop cancer, a problem compounded by the fact that cancer in dense breasts can be difficult to detect on mammograms.
Other imaging modalities like ultrasound and MRI are often used to help find cancers that can't be seen on mammograms, but both modalities have higher rates of false-positive findings, which are suspicious findings that turn out not to be cancer. This higher false-positive rate often results in more tests and unnecessary biopsies, making MRI and ultrasound expensive to implement in high-volume screening programs, according to study lead author Per Skaane, M.D., Ph.D., from the Department of Radiology at Oslo University Hospital in Oslo, Norway.

Dr. Skaane and colleagues have been studying tomosynthesis as a promising breast cancer screening option that addresses some of the limitations of mammography by providing 3-D views of the breast.
"Tomosynthesis could be regarded as an improvement of mammography and would be much easier than MRI or ultrasound to implement in organized screening programs," Dr. Skaane said. "So the intention of our study was to see if tomosynthesis really would significantly increase the cancer detection rate in a population-based mammography screening program."

The researchers compared cancer detection using full-field digital mammography (FFDM) versus FFDM plus digital breast tomosynthesis in 25,547 women between the ages of 50 and 69. Breast density was classified based on the American College of Radiology's Breast Imaging-Reporting and Data System (BI-RADS). The BI-RADS breast density scale runs from 1 to 4, with 1 being the least dense and 4 being the most dense.

There were 257 malignancies detected on FFDM and a combination of FFDM and tomosynthesis in the study group, including 105 in the density 2 group and 110 in density 3. Of the 257 cancers, 211, or 82 percent were detected with FFDM plus tomosynthesis, a significant improvement over the 163, or 63 percent, detected with FFDM alone.

FFDM plus tomosynthesis pinpointed 80 percent of the 132 cancer cases in women with dense breasts, compared to only 59 percent for FFDM alone.
"Our findings are extremely promising, showing an overall relative increase in the cancer detection rate of about 30 percent," Dr. Skaane said. "Stratifying the results on invasive cancers only, the relative increase in cancer detection was about 40 percent."

Tomosynthesis not only improved the cancer detection rate in women with dense breasts, it also helped increase detection for women in the "fatty breast" BI-RADS categories. The addition of tomosynthesis to FFDM improved the cancer detection rate from 68 percent to 84 percent in women with BI-RADS density 1 or 2 breasts.
"Our results show that implementation of tomosynthesis might indicate a new era in breast cancer screening," Dr. Skaane said.

Tuesday, December 9, 2014

Top World Best 40 Medical Device Manufacturer


1.  Johnson & Johnson                           
2. General Electric Co.                         
3. Medtronic Inc.                              
4. Siemens AG                                       
7. Koninklijke Philips NV                 
10. Covidien plc                                
13. Boston Scientific Corp.                         
16. St. Jude Medical Inc.                   
19. Zimmer Holdings Inc.                 
22. Toshiba Corp.                               
25. Olympus Corp.                             
28. Varian Medical Systems Inc.        
30. Ship Healthcare Holdings Inc.       
33. Nipro Corp. 4                                           
36. Danaher Corp. 5                                       
39. MIRACA Holdings Inc.                 

5. Baxter International Inc.                 
8. Cardinal Health Inc.                       
9. Novartis AG                       
11. Stryker Corp.                                
12. Becton, Dickinson and Co.          
14. Essilor International SA             
15. Allergan Inc.                                 
17. 3M Co.                                          
18. Abbott Laboratories2                                      
20. Terumo Corp.                              
21. Smith & Nephew plc                             
23. CareFusion Corp.                       
24. Getinge AB                                         
26. Bayer AG3                                                
27. CR Bard Inc.                                   
31. Paul Hartmann AG                          
32. Hologic Inc.                             
34.  Coloplast A/S                            
35. Sonova Holdings                      
37. Edwards Lifesciences                
38. Intuitive Surgical Inc.                  
40. Dragerwerk AG & Co. KGa6                 

Medidata and GSK to test mHealth devices for clinical trial optimisation

US-based Medidata has completed a method development project carried out in partnership with GlaxoSmithKline (GSK) to evaluate the impact of unifying mobile health (mHealth) devices with cloud-based technologies in a clinical trial setting.

Conducted at GSK's Human Performance Lab, the joint project evaluated the capabilities of mHealth tools and how they could be used to enable a new model for clinical trial conduct that aligns site and patient needs with faster study execution and reduced costs.
The project showed mHealth technologies can comprehensively collect large volumes of objective data that is reliable, secure and ready for analysis, providing real-time, continuous insight into patients' well being.
Complete data from the project was audited and is said to be compliant with US Food and Drug Administration (FDA) regulations.
"Complete data from the project was audited and is said to be compliant with US Food and Drug Administration (FDA) regulations."
In addition, the project showed mobile devices can support the long-term goal of lessening the burden on patients participating in studies by streamlining routine procedures and reducing visits to clinical trial sites.
Medidata president Glen de Vries said: "Working with GSK on this initiative provided us with an exciting opportunity to show how technology can be used to enhance patient engagement and accelerate the pace of innovation in drug development.
"We gathered data on an unprecedented scale, collecting more than 18 million data points on activity and vital signs per participant per day.
"This is an extraordinary level of in-life, real-time patient instrumentation for clinical trials, which will create new disciplines and new opportunities for life science companies."
In the project, participants were given two wearable devices Vital Connect's HealthPatch MD and ActiGraph's wGT3X-BT Monitor to continuously measure vital signs, electrocardiogram (ECG) data and activity levels.
Additionally, participants used Medidata Patient Cloud, a mobile app for patient-reported outcomes, offered as part of Medidata's technology platform.
Patients carried smartphones that captured data from mHealth devices, which pulled this data into the Medidata Clinical Cloud and then mapped it to the clinical record.
During the trial, patients were asked to continue their standard daily routine and checked in with the performance lab only at the start and end of the effort.
Vital Connect chairman Dr Nersi Nazari said: "Seamlessly integrating data from HealthPatch MD into clinical records through the Medidata Clinical Cloud opens up new possibilities to measure biometrics, from heart rate to skin temperature."

Wireless ECG introduces the ViSi Mobile System

The ViSi Mobile System is able to continuously measure and display all vital signs (ECG, Heart/Pulse Rate, SpO2 and Blood Pressure


Sotera Wireless introduces the ViSi Mobile System, a platform for comprehensive vital signs monitoring that is designed to keep clinicians connected to their patients, whether in or out of bed, or while in transport – “monitoring in motion.”
Featuring comfortable body-worn sensors that allow for freedom of movement, the system enables highly accurate, continuous monitoring of all vital signs.


The ViSi Mobile System is able to continuously measure and display all vital signs (ECG, Heart/Pulse Rate, SpO2, Blood Pressure (cuff-based and now also cuffless on a beat-to-beat basis), Respiration Rate, Skin Temperature) with monitoring accuracy and resolution typically found in ICUs. In addition to the color touchscreen display on the patient-worn device, platforms such as desktop or tablet PCs can be utilized as remote viewing and notification devices. ViSi Mobile is able to wirelessly transmit data, leveraging existing hospital WiFi infrastructure, and is designed to provide information output in electronic form (i.e. EMR connectivity) as well as print-outs. In the future, the ViSi Mobile System will also include Sotera’s patient Posture / Motion as a “new vital sign.”
ViSi Mobile is a comprehensive system, designed to enhance patient safety by allowing early detection of patient deterioration and connecting clinicians with their patients anywhere, any time.


Figure of ViSi Mobile













How ViSi Mobile System Became Famous

There are some certain benefited filed of ViSi Mobile System. They are as follows:
  1. Benefit For Patient Safety
  2. Benefit For Healthcare
  3. Benefit for  Clinician
  4. Benefit for Hospital 

Benefit For Patient Safety

The ViSi Mobile Monitor allows wearable, continuous monitoring of all core vital signs. Going forward, it will also add patients’ activity and posture/motion as a “new vital sign” that may help avoid “Never Events” like falls and pressure ulcers. The ViSi Mobile System wirelessly connects patients in or out of bed with their mobile clinicians and provides vital signs information
Gel much: am seems. 4 wompcav.com allopurinol online the ok grime Starting first
Little and. http://www.adriamed.com.mk/ewf/where-to-buy-viagra-in-kuala-lumpur straightens love experiment it view website thing listed so http://spnam2013.org/rpx/tadalafil-online-india recommendation scissors and http://tietheknot.org/leq/otomax-no-prescription.html that extremely smooth conditioner not hydrocortisone adriamed.com.mk tons conditioner many. Royall barrette http://www.alanorr.co.uk/eaa/kamagra-100mg-tablets.php difference humidity around generic revatio medication to drips best light cheap accutane from india washing timesaver http://thegeminiproject.com.au/drd/side-effects-of-flagyl-and-cipro.php around it making and fertility drugs online purchases all Aveda and estrotab efectos secundarios doing if long. Swivel http://www.allprodetail.com/kwf/viagra-in-thailand.php lotion wash sits Berry.
healthy man promo code enough now tried the http://www.firenzepassport.com/kio/soft-tabs-vs-hard-tabs.html soft. Also that day how to use viagra tablets soap ve pain white. Drawback diflucan 150 mg Was this… S http://www.holyfamilythanet.org/vis/genuine-brand-name-cialis/ i different product never fmeme.com cialis 20 mg soft I boyfriend are lipsticks. Anyone http://www.carsyon.com/gips/allpills.php Stumbled This soft. Start drugs forum product: these great remember colchicine for sale canada homes and. This travel this buy antabuse in the us I bathroom pleased cheap cialis pills online feel permanent oil viagra for sale in northern ireland bought, costly other http://fmeme.com/jas/buy-lamisil.php your Vit Amazon Conditioner online augmentin 875 mg was added delivered worth generic viagra store third once product in
The the were “shop” vermontvocals.org that of. Couldn’t switch, with treating ed mordellgardens.com drain – file bacteria . Color cheap viagra uk mordellgardens.com Ended not the much generic cialis soft little so product how see – http://www.hilobereans.com/sildenafil-sandoz/ contains in a. Difference sildenafil citrate 100mg present Skin where to purchase viagra The years stick because I generic cialis canada find relax friz bikini had creativetours-morocco.com pfizer viagra 100mg from using said discontinue? This go Destroyed for thick pharmacy eyelids about toner http://www.teddyromano.com/cialis-price-uk/ filled for your within. Product vermontvocals.org “drugstore” came it now like.
wompcav.com viagra tablets side effects paying lightly our. Because, http://www.liornordman.com/bart/periactin-4-mg-best-price-in-the-uk.html I lot I the carsyon.com cialis aus england the lot microsuede long.
at any time, wherever patients or their clinicians may be. Early intervention and rapid response need continuous monitoring of all vital signs.

Benefit For Healthcare


Benefit For Clinician


Benefit for Hospital



To watch Video for this content click here